TipRanks
Advertisement
Advertisement
Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained
PremiumRatingsOlema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained
1M ago
Olema Oncology reports Q2 EPS (61c), consensus (56c)
Premium
The Fly
Olema Oncology reports Q2 EPS (61c), consensus (56c)
1M ago
OLMA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
OLMA Earnings this Week: How Will it Perform?
1M ago
Olema Pharmaceuticals: Buy Rating Reiterated as Pipeline Progress Supports Attractive Risk/Reward with Unchanged $62 Price Target
PremiumRatingsOlema Pharmaceuticals: Buy Rating Reiterated as Pipeline Progress Supports Attractive Risk/Reward with Unchanged $62 Price Target
4M ago
Olema Oncology announces collaboration, supply agreement with Bayer
Premium
The Fly
Olema Oncology announces collaboration, supply agreement with Bayer
4M ago
Olema, Bayer launch OP-3136 prostate cancer collaboration
Premium
Company Announcements
Olema, Bayer launch OP-3136 prostate cancer collaboration
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100